Diligence memo · auto-generated · as of July 2, 2026

Cerimon Pharmaceuticals, Inc.

Cerimon Pharmaceuticals, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Cerimon Pharmaceuticals, Inc. operates in Pharmaceuticals, based in SOUTH SAN FRANCISCO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Cerimon Pharmaceuticals, Inc. has raised $3.7M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.5M on 2009-09-02.

Most recent recorded round closed around 2010-11-01.

Valuation (modeled)modeled

Provath models Cerimon Pharmaceuticals, Inc. at approximately $8.9M (range $176K–$70M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.15× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 3 months.

Last raise 15.7 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 37% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 15% of those peers.

Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.

Peoplefiled

16 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.